Literature DB >> 23813956

Scribble regulates an EMT polarity pathway through modulation of MAPK-ERK signaling to mediate junction formation.

Imogen A Elsum1, Claire Martin, Patrick O Humbert.   

Abstract

The crucial role the Crumbs and Par polarity complexes play in tight junction integrity has long been established, however very few studies have investigated the role of the Scribble polarity module. Here, we use MCF10A cells, which fail to form tight junctions and express very little endogenous Crumbs3, to show that inducing expression of the polarity protein Scribble is sufficient to promote tight junction formation. We show this occurs through an epithelial-to-mesenchymal (EMT) pathway that involves Scribble suppressing ERK phosphorylation, leading to downregulation of the EMT inducer ZEB. Inhibition of ZEB relieves the repression on Crumbs3, resulting in increased expression of this crucial tight junction regulator. The combined effect of this Scribble-mediated pathway is the upregulation of a number of junctional proteins and the formation of functional tight junctions. These data suggests a novel role for Scribble in positively regulating tight junction assembly through transcriptional regulation of an EMT signaling program.

Entities:  

Keywords:  EMT; ERK; Mammary epithelium; Polarity; Scribble; Tight junctions

Mesh:

Substances:

Year:  2013        PMID: 23813956     DOI: 10.1242/jcs.129387

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  46 in total

Review 1.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 2.  DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity.

Authors:  Nanyue Chen; Seetharaman Balasenthil; Jacquelyn Reuther; Ann McNeill Killary
Journal:  Cancer Res       Date:  2014-09-26       Impact factor: 12.701

Review 3.  Modeling Tissue Polarity in Context.

Authors:  Kevin M Tharp; Valerie M Weaver
Journal:  J Mol Biol       Date:  2018-07-25       Impact factor: 5.469

4.  Scribble acts as an oncogene in Eμ-myc-driven lymphoma.

Authors:  E D Hawkins; J Oliaro; K M Ramsbottom; A Newbold; P O Humbert; R W Johnstone; S M Russell
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

5.  The de-ubiquitinase UCHL1 promotes gastric cancer metastasis via the Akt and Erk1/2 pathways.

Authors:  Yu-yu Gu; Mei Yang; Mei Zhao; Qing Luo; Lin Yang; Hua Peng; Jia Wang; Sheng-kai Huang; Zhao-xu Zheng; Xing-hua Yuan; Ping Liu; Chang-zhi Huang
Journal:  Tumour Biol       Date:  2015-05-28

6.  Crumbs 3b promotes tight junctions in an ezrin-dependent manner in mammalian cells.

Authors:  Andrew M Tilston-Lünel; Kathryn E Haley; Nicolas F Schlecht; Yanhua Wang; Abigail L D Chatterton; Susana Moleirinho; Ailsa Watson; Harinder S Hundal; Michael B Prystowsky; Frank J Gunn-Moore; Paul A Reynolds
Journal:  J Mol Cell Biol       Date:  2016-10-01       Impact factor: 6.216

Review 7.  Research advances in HMGN5 and cancer.

Authors:  Zhan Shi; Run Tang; Ding Wu; Xiaoqing Sun
Journal:  Tumour Biol       Date:  2015-12-23

8.  Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.

Authors:  Michael E Feigin; S Dipikaa Akshinthala; Kiyomi Araki; Avi Z Rosenberg; Lakshmi B Muthuswamy; Bernard Martin; Brian D Lehmann; Hal K Berman; Jennifer A Pietenpol; Robert D Cardiff; Senthil K Muthuswamy
Journal:  Cancer Res       Date:  2014-03-24       Impact factor: 12.701

9.  Expression of polarity genes in human cancer.

Authors:  Wan-Hsin Lin; Yan W Asmann; Panos Z Anastasiadis
Journal:  Cancer Inform       Date:  2015-03-30

10.  KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers.

Authors:  Kyung-Hwa Lee; Eun-Jung Ahn; Se-Jeong Oh; Ok Kim; Young-Eun Joo; Jeong-A Bae; Somy Yoon; Hyang-Hwa Ryu; Shin Jung; Kyung-Keun Kim; Jae-Hyuk Lee; Kyung-Sub Moon
Journal:  Oncotarget       Date:  2015-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.